Aspen's slippery slope in Italy
19 October 2016 - 09:28
Aspen Pharmacare, South Africa's generic drug manufacturer, has been fined €5-million (about R77-million) by Italy's competition authorities for increasing the prices of old blood-cancer drugs, potentially disrupting the supply of them. Aspen is the only supplier of these older drugs, which are used in some blood cancers and blood disorders, to Italy after buying the rights from GlaxoSmithKline.
This article is reserved for Sunday Times subscribers.
A subscription gives you full digital access to all Sunday Times content.
Please visit SundayTimes.co.za in your desktop to view our latest subscription options.
Already subscribed? Simply sign in below.
Sign InQuestions or problems? Email helpdesk@timeslive.co.za or call 0860 52 52 00.